Evidence map›Paper›PMID 25551221›Full record

ArticlePloS one2014

Angiotensin II receptor blocker ameliorates stress-induced adipose tissue inflammation and insulin resistance.

Motoharu Hayashi, Kyosuke Takeshita, Yasuhiro Uchida, Koji Yamamoto, Ryosuke Kikuchi, Takayuki Nakayama, Emiko Nomura, Xian Wu Cheng, Tadashi Matsushita, Shigeo Nakamura and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Transcriptomic alterations in hypertrophy of the ligamentum flavum: interactions of Rho GTPases, RTK, PIK3, and FGF.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2023
    Article
  5. Review
  6. Statins Mitigate Stress-Related Vascular Aging and Atherosclerosis inFrontiers in cell and developmental biology · 2021
    Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Motoharu HayashiDepartment of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kyosuke TakeshitaDepartment of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Clinical Laboratory, Nagoya University Hospital, Nagoya, Japan.
Yasuhiro UchidaDepartment of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Koji YamamotoDepartment of Blood Transfusion, Nagoya University Hospital, Nagoya, Japan.
Ryosuke KikuchiDepartment of Clinical Laboratory, Nagoya University Hospital, Nagoya, Japan.
Takayuki NakayamaDepartment of Blood Transfusion, Aichi Medical University Hospital, Nagakute, Japan.
Emiko NomuraDepartment of Blood Transfusion, Nagoya University Hospital, Nagoya, Japan.
Xian Wu ChengDepartment of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Tadashi MatsushitaDepartment of Blood Transfusion, Nagoya University Hospital, Nagoya, Japan.
Shigeo NakamuraDepartment of Pathology, Nagoya University Hospital, Nagoya, Japan.
Toyoaki MuroharaDepartment of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Nagoya University Hospital · JPNagoya University · JPAichi Medical University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A strong causal link exists between psychological stress and insulin resistance as well with hypertension. Meanwhile, stress-related responses play critical roles in glucose metabolism in hypertensive patients. As clinical trials suggest that angiotensin-receptor blocker delays the onset of diabetes in hypertensive patients, we investigated the effects of irbesartan on stress-induced adipose tissue inflammation and insulin resistance. C57BL/6J mice were subjected to 2-week intermittent restraint stress and orally treated with vehicle, 3 and 10 mg/kg/day irbesartan. The plasma concentrations of lipid and proinflammatory cytokines [Monocyte Chemoattractant Protein-1 (MCP-1), tumor necrosis factor-α, and interleukin-6] were assessed with enzyme-linked immunosorbent assay. Monocyte/macrophage accumulation in inguinal white adipose tissue (WAT) was observed with CD11b-positive cell counts and mRNA expressions of CD68 and F4/80 using immunohistochemistry and RT-PCR methods respectively. The mRNA levels of angiotensinogen, proinflammatory cytokines shown above, and adiponectin in WAT were also assessed with RT-PCR method. Glucose metabolism was assessed by glucose tolerance tests (GTTs) and insulin tolerance tests, and mRNA expression of insulin receptor substrate-1 (IRS-1) and glucose transporter 4 (GLUT4) in WAT. Restraint stress increased monocyte accumulation, plasma free fatty acids, expression of angiotensinogen and proinflammatory cytokines including MCP-1, and reduced adiponectin. Irbesartan reduced stress-induced monocyte accumulation in WAT in a dose dependent manner. Irbesartan treatment also suppressed induction of adipose angiotensinogen and proinflammatory cytokines in WAT and blood, and reversed changes in adiponectin expression. Notably, irbesartan suppressed stress-induced reduction in adipose tissue weight and free fatty acid release, and improved insulin tolerance with restoration of IRS-1 and GLUT4 mRNA expressions in WAT. The results indicate that irbesartan improves stress-induced adipose tissue inflammation and insulin resistance. Our results suggests that irbesartan treatment exerts additive benefits for glucose metabolism in hypertensive patients with mental stress.

Indexed as

Insulin ResistanceAdipokinesAdipose Tissue, WhiteAngiotensin II Type 1 Receptor BlockersAngiotensinogenAnimalsBiphenyl CompoundsChemokine CCL2Disease Models, AnimalDose-Response Relationship, DrugIrbesartanLipolysisMaleMice, Inbred C57BLPanniculitisStress, PhysiologicalAdipokinesAngiotensin II Type 1 Receptor BlockersAngiotensinogenBiphenyl CompoundsCcl2 protein, mouseChemokine CCL2IrbesartanTetrazoles

Identifiers

PMID25551221
PMCPMC4281136
OpenAlexW2032724225

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.